Emcure Pharmaceuticals Ltd

Emcure Pharmaceuticals Limited's Board of Directors has approved a Composite Scheme of Amalgamation involving its wholly-owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, with the parent company. The amalgamation aims to achieve entity rationalization and operational efficiency within the group. Zuventus Healthcare Limited had a net worth of ₹871.46 crore and a turnover of ₹1,040.58 crore for FY 2025-26. Emcutix Biopharmaceuticals Limited had a net worth of (₹13.07) crore and a turnover of ₹29.37 crore. Emcure Pharmaceuticals Limited reported a net worth of ₹3,710.60 crore and a turnover of ₹5,243.19 crore. No cash consideration will be paid as the entire share capital of the transferor companies is held by Emcure. The scheme is subject to necessary statutory and regulatory approvals, including from the National Company Law Tribunal (NCLT), Mumbai Bench. This amalgamation is considered exempt from related party transaction regulations.

Emcure Pharmaceuticals Limited has received orders from the Income-tax Department imposing an aggregate penalty of ₹57,73,96,732 for the financial years 2014-15 to 2020-21. The company is currently evaluating legal remedies, including filing an appeal. This penalty relates to ongoing litigations previously disclosed by the company. The opposing party is the Deputy Commissioner of Income Tax, Central Circle (1)- Pune. The litigation was initiated on December 27, 2023.

Emcure Pharmaceuticals Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will be shut effective October 01, 2026, and will reopen 48 hours after the declaration of the company's unaudited financial results for the quarter and half-year ending September 30, 2026. The specific date for the board meeting to approve these results will be communicated later. The company has also uploaded this intimation on its website.

Emcure Pharmaceuticals Ltd announced changes in its Board composition following its 45th Annual General Meeting (AGM) held on September 21, 2026. Mr. Berjis Desai retired as Chairman and Non-Executive Non-Independent Director. The members also approved the re-appointment of Dr. Mukund Gurjar as Whole-time Director for one year from August 28, 2026, and Mr. Satish Mehta as Managing Director & CEO for five years from April 1, 2027. Additionally, Mr. Raghu Kumar was appointed as an Independent Director for a three-year term effective August 6, 2026. Voting results were submitted to stock exchanges on September 23, 2026.

Emcure Pharmaceuticals Ltd has dispatched letters to its members whose email addresses are not registered with the company or depository participants. These letters contain a web-link and QR code for the Annual Report 2025-26 and the Notice of the 45th Annual General Meeting (AGM). The AGM is scheduled for September 21, 2026, to be held via Video Conferencing. The dispatch is in compliance with SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company also reminded members to submit documents for TDS exemption on final dividend and update KYC details, including PAN, address, bank details, and specimen signature, especially for those holding physical securities.

Emcure Pharmaceuticals Ltd. has filed its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26. The report, which forms an integral part of the company's Annual Report, details Emcure's commitment to responsible business practices, sustainable growth, ethical governance, and creating long-term stakeholder value. Key focus areas include enhancing healthcare accessibility globally, strengthening environmental stewardship through resource efficiency and emission reduction, fostering a safe and inclusive workplace, contributing to community development via CSR initiatives, and reinforcing governance through transparency and robust risk management. The company aims to integrate sustainability principles across its value chain and operations.

Emcure Pharmaceuticals Limited has announced its 45th Annual General Meeting (AGM) will be held on Monday, September 21, 2026, at 11:00 a.m. IST. The meeting will be conducted entirely through Video Conferencing (VC) / Other Audio-Visual Means (OAVM), with no physical presence of members at a common venue, in line with MCA and SEBI circulars. Members holding shares as of the cut-off date, September 14, 2026, are eligible to attend and participate via the VC/OAVM platform provided by MUFG Intime India Private Limited. The notice of the AGM and the Annual Report for the Financial Year 2025-26 are available on the company's website and MUFG Intime's website. Remote e-voting will be open from Friday, September 18, 2026, 9:00 a.m. IST, to Sunday, September 20, 2026, 5:00 p.m. IST.

Emcure Pharmaceuticals Limited has announced its Annual Report for the Financial Year 2025-26, along with the Notice of its 45th Annual General Meeting (AGM). The AGM is scheduled for Monday, September 21, 2026, at 11:00 a.m. IST, to be conducted via Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Members holding shares as of Monday, September 14, 2026, are eligible to attend and participate in remote e-voting, which will be open from Friday, September 18, 2026, 9:00 a.m. IST, to Sunday, September 20, 2026, 5:00 p.m. IST. The report highlights key financial and operational achievements, including revenue from operations of INR 92,035 Mn, ROCE of 23.7%, and an EBITDA margin of 19.4%. The company operates in over 80 countries and holds the #2 rank in Gynaecology in India.

Emcure Pharmaceuticals Ltd has announced the receipt of the Establishment Inspection Report (EIR) from the United States Food & Drug Administration (USFDA) for its formulations facility located in Sanand, Ahmedabad, Gujarat. The USFDA has classified the inspection status of this facility as Voluntary Action Indicated (VAI), signifying that the inspection is now closed. This update follows a previous intimation regarding the inspection conducted between May 06, 2026, and May 15, 2026. The VAI classification is generally viewed positively by the market as it indicates no major compliance issues requiring significant corrective actions.

Emcure Pharmaceuticals Ltd has announced that its 45th Annual General Meeting (AGM) will be held on Monday, September 21, 2026, at 11:00 a.m. IST via Video Conferencing. The company's Board of Directors had previously recommended a final dividend of ₹3.60 per equity share (36%) for the financial year ended March 31, 2026. The record date for determining the entitlement of members to this final dividend has been fixed as Friday, September 04, 2026. If approved at the AGM, the dividend payment will be made within 30 days of the approval, subject to applicable taxes.